Labcorp (LH) Projected to Announce Earnings on Thursday

Labcorp (NYSE:LH) is projected to issue its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of $4.79 per share and revenue of $3.7094 billion for the quarter. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 9:00 AM ET.

Labcorp (NYSE:LH) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $4.09 by $0.16. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The firm had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.51 billion. During the same quarter in the prior year, the company earned $3.84 EPS. The company’s revenue was up 5.8% compared to the same quarter last year. On average, analysts expect Labcorp to post $18 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Labcorp Price Performance

NYSE LH opened at $314.82 on Wednesday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.54 and a current ratio of 1.73. The firm’s 50 day moving average price is $271.54 and its 200-day moving average price is $269.92. Labcorp has a 52-week low of $244.52 and a 52-week high of $315.77. The company has a market cap of $25.82 billion, a PE ratio of 27.89, a P/E/G ratio of 2.00 and a beta of 0.89.

Labcorp Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be issued a dividend of $0.72 per share. The ex-dividend date is Friday, August 28th. This represents a $2.88 dividend on an annualized basis and a yield of 0.9%. Labcorp’s dividend payout ratio is currently 25.51%.

Insider Buying and Selling

In related news, EVP Kathryn W. Kyle sold 762 shares of the stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $263.89, for a total transaction of $201,084.18. Following the completion of the sale, the executive vice president owned 3,813 shares of the company’s stock, valued at $1,006,212.57. This represents a 16.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Bryan T. Vaughn sold 234 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total transaction of $66,968.46. Following the completion of the sale, the executive vice president owned 6,746 shares of the company’s stock, valued at approximately $1,930,637.74. This trade represents a 3.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 6,991 shares of company stock worth $1,796,696 in the last 90 days. 0.84% of the stock is owned by corporate insiders.

Institutional Trading of Labcorp

A number of institutional investors have recently made changes to their positions in LH. Wellington Management Group LLP raised its stake in shares of Labcorp by 15.9% in the third quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock worth $604,488,000 after purchasing an additional 289,029 shares during the last quarter. Marshall Wace LLP boosted its position in Labcorp by 79.1% in the third quarter. Marshall Wace LLP now owns 623,550 shares of the medical research company’s stock valued at $178,996,000 after buying an additional 275,454 shares during the last quarter. Millennium Management LLC boosted its position in Labcorp by 2,491.3% in the fourth quarter. Millennium Management LLC now owns 277,323 shares of the medical research company’s stock valued at $69,575,000 after buying an additional 266,621 shares during the last quarter. Woodline Partners LP increased its holdings in Labcorp by 598.1% in the 3rd quarter. Woodline Partners LP now owns 287,146 shares of the medical research company’s stock worth $82,428,000 after buying an additional 246,014 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in Labcorp by 19.8% in the 4th quarter. JPMorgan Chase & Co. now owns 1,287,177 shares of the medical research company’s stock worth $322,927,000 after buying an additional 213,136 shares during the period. Institutional investors and hedge funds own 95.94% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Robert W. Baird increased their target price on Labcorp from $335.00 to $338.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Bank of America boosted their price target on Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Weiss Ratings raised Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday. Finally, Evercore reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Labcorp in a research report on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $315.33.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.